Media, Inc.

All Penny News: Athersys Partners to Expand MultiStem for Ischemic Stroke to Japan


Mississauga, ON -- (SBWIRE) -- 03/03/2015 -- Media, Inc. ( announces its latest article titled "Athersys Partners to Expand MultiStem for Ischemic Stroke to Japan."

Companies mentioned in this article include Athersys, Inc. (NASDAQ:ATHX).

Article Excerpt:

"I think that people across the world in the next couple years are going to be as blown away as I was with our father when they see the power of stem cells and what they do for patients with not just stroke but with dementia and traumatic brain injuries and spinal cord injuries." That's what Dr. Murray Howe, head of the radiology department at ProMedica Toledo Hospital and son of Mr. Hockey Gordie Howe, recently told CBS Detroit about an experimental stem cell treatment in Mexico that has delivered a positive response for his father, who suffered a stroke in October.

Strokes are a leading killer and major strain on healthcare systems worldwide, with little currently available for treatment. The standard is the clot-buster tPA, or tissue plasminogen activator, but it must be administered within three to four hours from the onset of the stoke for any chance of improving clinical outcome. Sadly, most of the nearly 800,000 Americans and 15 million people globally that suffer a stroke each year don't make it to the hospital in time for this limited therapeutic option. Approximately 130,000 Americans die each year from a stroke, or 1 out of every 20 deaths, according to the Centers for Disease Control and Prevention. Ischemic stroke (a result of an obstruction within a blood vessel supplying blood to the brain) is far and away the most prominent form, accounting for about 8 out of every 10 stroke cases.

There are more than 50 clinical trials going on around the world testing the safety and efficacy of stem cells to treat ischemic stroke patients, with favorable data coming from many. In that vein, investors should be starting to look ahead to results from a Phase 2 trial by Athersys, Inc. (NASDAQ:ATHX) on its cell therapy product called MultiStem expected in April. MultiStem is an allogeneic, "off-the-shelf" regenerative medicine product with a unique mechanism of action that has been shown in laboratory and clinical settings to have the ability to, amongst other things, reduce inflammation and promote tissue repair and healing, producing a significant and durable response for multiple indications. Importantly in the case of stroke, Athersys is looking to open the window of treatment time to days (perhaps up to a week), instead of only a few hours to improve clinical outcomes.

The full version of this article can be found at:

About is focused on the small-cap / penny stock market and has become a reputable name in the investment community. runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor. also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria looks for includes strong revenues, a seasoned management, innovative business plans, among many others. also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here:

Contact: Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: /

Note: has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: